Navigation Links
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Date:11/30/2011

>

Modifying the genetic risk for myocardial infarction 19

Management of heart failure 19

Management of hypertension 20

Pharmacogenomics of diuretic drugs 20

Pharmacogenomics of ACE inhibitors 20

Management of hypertension by personalized approach 21

Pharmacogenetics of lipid-lowering therapies 21

Polymorphisms in genes involved in cholesterol metabolism 21

Role of eNOS gene polymorphisms 22

Important advances in cardiovascular therapeutics 22

Drug delivery, biotechnology and the cardiovascular system 23

Role of cardiovascular imaging in cardiovascular therapeutics 23

Chronopharmacotherapy of cardiovascular diseases 23

2. Methods for Drug Delivery to the Cardiovascular System 25

Introduction 25

Routes of drug delivery to the cardiovascular system 25

Local administration of drugs to the cardiovascular system 25

Intramyocardial drug delivery 25

Drug delivery via coronary venous system 26

Intrapericardial drug delivery 26

Formulations for drug delivery to the cardiovascular system 27

Sustained and controlled release 27

Programming the release at a defined time 28

Dosage formulation of calcium channel blockers 28

Sustained and controlled release verapamil 28

Methods of administration of proteins and peptides 28

Delivery of peptides by subcutaneous injection 29

Depot formulations and implants 29

Poly(ethylene glycol) technology 29

Microencapsulation for protein delivery 30

Localized delivery of biomaterials for tissue engineering 30

Oral delivery of proteins and peptides 30

DDS to improve systemic delivery of cardiovascular drugs 32

Nanotechnology-based drug delivery 32

Controlled delivery of nanoparticles to injured vasculature 33

Nanoparticles for cardiovascular imaging and targeted drug delivery 34

Nanofiber-based scaf
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cynosure to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference
2. CryoLife to Present at 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference
3. New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI
4. The Global Cardiovascular Monitoring & Diagnostic Devices Market is Booming: Expected to Attain a Market Size of USD 1.3 Billion by 2016
5. MAQUET Cardiovascular Announces FDA 510(k) Clearance and CE Mark for the CARDIOSAVE™ Intra-Aortic Balloon Pump
6. CVS Caremark Launches Chronic Cardiovascular Disease Medication Adherence Program
7. MAQUET Cardiovascular Completes Acquisition of Atrium Medical Corporation
8. Beating Cardiovascular Disease: Continuing Medical Education Course (CME) in Jackson, MS
9. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
10. DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage
11. Global Cardiovascular Drug Market: Strategic Assessments of Leading Suppliers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today ... Total revenue was $2.6 million and $8.2 million for the ... million and $3.8 million for the same periods in 2010. ... September 30, 2011, were $9.0 million and $24.0 million as compared ...
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11
(Date:12/25/2014)... Hills, California (PRWEB) December 25, 2014 ... her home in Woodland Hills, California after an 8 ... passed away on Christmas Eve evening in her home ... with aggressive metastatic breast cancer. , ... for over forty years, she pioneered and championed many ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... Carolina (PRWEB) December 25, 2014 ... Carolina Retirement Community, recently showed their generous spirit ... of the Catawba County Parenting Network- Grandparents Raising ... 10 children gathered around the largest Christmas tree ... open presents purchased by residents of the Abernethy ...
Breaking Medicine News(10 mins):Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Cardium Therapeutics,(Amex: CXM ) today announced the completion ... debt with accompanying warrants to purchase shares of,common stock, ... paid,off last quarter. Empire Asset Management Company acted as ... and the Barone,Group acted as lead investor. The material ...
... cause short-term neurological problems in children and teenagers ... to pediatric researchers. The new finding contrasts favorably ... after newborn surgery for more complex heart conditions. ... who receive surgery for these less complex heart ...
... a Tucson based,drug delivery device company, announced the ... to the company,s medical Advisory Board. Both,Swenson and ... Hospital, Hospice and Home care settings., David ... Medical,Center and the Fred Hutchinson Cancer Research Center ...
... 10 Text messaging has,rapidly become a favorite form ... is a public health risk, says the American,Medical Association ... meeting. The AMA voted today to advocate for state,legislation ... while,driving., "Texting while driving takes the driver,s attention ...
... was tied to eye infection outbreak in U.S. , , ... high temperatures degrades the antifungal properties of the ReNu ... a U.S. eye infection outbreak between 2004 and 2006, ... a microbial agent not found in other contact lens ...
... On November 3, 2008,The Centers for Medicare ... a new code E0770 with the descriptor (functional,electrical ... type, complete system, not otherwise specified) which will ... incomplete spinal cord,injuries effective January 1, 2009. This ...
Cached Medicine News:Health News:Cardium Completes $6.0 Million Financing 2Health News:Cardium Completes $6.0 Million Financing 3Health News:Cardium Completes $6.0 Million Financing 4Health News:No drop in IQ seen after bypass for child heart surgery 2Health News:Medipacs Appoints Advisory Board Members 2Health News:High Temps Degrade Contact Lens Solution: Study 2Health News:Hanger Orthopedic Group, Inc. Receives Favorable New Code for WalkAide 2Health News:Hanger Orthopedic Group, Inc. Receives Favorable New Code for WalkAide 3
Platelet Aggregation Profiler...
... Eclipse,Plus or 850 ECG medical ... capability. Doctors,maintain all the benefits ... and gain the,ability to view ... personal computers., With diagnostic-quality viewing ...
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
... provides three contrast levels (high, 9.5 % and ... This test is designed to detect very subtle ... lens evaluation or due to refractive surgery. The ... same contrast and acuity levels as the lower ...
Medicine Products: